Denise Myshko

But there is no benefit for patients receiving chemotherapy.

Kite plans to submit a supplemental BLA based on these findings.

Regulatory actions for drugs for children, a combination cancer therapy, launches of two generic therapies for COPD, and cancer and Alzheimer’s therapies receive Breakthrough Designation round out this week’s FDA news.

Implementation of value-based approaches requires measurement of value, authors said.

The anticancer therapy is now available in 21-count bottles to help accommodate dispensing.

The two organizations have created a fellowship program to help improve patient outcomes and reduce costs.

Positive findings for Tepmetko and Tabrecta reported at ASCO.

The therapy would be used to help prevent and treat blood clots in pediatric patients.

Understanding medication utilization patterns is important for future evaluations of clinical outcomes, investigators say.

A longstanding four times per day testing requirement will cease, and patients using inhaled insulin now qualify for continuous glucose monitoring.

A new indication, a nonprescription switch, a recall, and new guidances round out this week’s FDA news.

Regardless of political affiliation, the public supports congressional action to allow the federal government to negotiate prices.

Although Lorbrena can improve health outcomes, it is not as cost-effective an option compared with Xalkori.

The therapy is a modified poliovirus vaccine that not only kills cancer cells but also can trigger long-term immune memory.

The Supreme Court’s dismissal of the latest challenge means patients will have access to lower-cost therapies, an advocacy group says.

The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.

Chances of left ventricular ejection fraction almost disappeared when patient took the ACE-inhibitor lisinopril during treatment with trastuzumab/anthracycline, according to research presented at ASCO.

Immune-related AEs can occur one to two years after treatment, are more common in combination treatments, and can be difficult to manage.

Three commercial plans now cover the corticosteroid Eysuvis.